Safety study of pitavastatin nanoparticles for retinitis pigmentosa
Part of Eyes & vision, Genetic & congenital clinical trials.
This trial tests a new form of the drug pitavastatin, which is usually used for cholesterol, but here it's given as tiny particles injected into the eye. The goal is to see if it's safe and might help people with retinitis pigmentosa, a condition that causes vision loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be diagnosed with typical retinitis pigmentosa by two eye doctors.
- You must be between 18 and 70 years old.
- You must have a certain level of remaining central vision (at least 10 dB average sensitivity within the central 4 degrees).
- Your vision must be stable, meaning the difference between two tests is within 3 dB.
- You must have a foveal (center of the retina) thickness of 250 micrometers or less.
- You must agree to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new peptide therapy for people with retinitis pigmentosa (RP), a genetic eye disease that causes vision loss. The goal is to see if the treatment is safe and can help slow or improve vision loss.
This trial tests a gentle laser treatment (SML) for people with retinitis pigmentosa (RP), an inherited eye disease that slowly causes vision loss. The goal is to see if the laser can help slow or improve vision problems like night blindness and tunnel vision.
This study tests a 24-month treatment with NPI-001, an oral medication, to see if it can slow the loss of light-sensing cells in the retina for people with retinitis pigmentosa tied to Usher syndrome. It aims to preserve remaining vision and delay further damage.
This study tests a new gene therapy called UGX202 for people with advanced retinitis pigmentosa, an eye disease that causes vision loss. The goal is to see if it is safe and if it can help improve vision.
This study tests a new gene therapy that may help people with advanced retinitis pigmentosa see better. It uses a modified virus to deliver a light-sensitive protein to the retina, and the trial compares the real treatment to a sham (fake) procedure to check safety and effectiveness.
This trial tests an investigational gene therapy injection (UGX202) for people with advanced retinitis pigmentosa. The goal is to see if the injection is safe and can help preserve or improve vision in people who still have some memory of seeing.
Hear when a new Retinitis Pigmentosa (RP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.